[go: up one dir, main page]

MX2009012879A - Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye. - Google Patents

Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye.

Info

Publication number
MX2009012879A
MX2009012879A MX2009012879A MX2009012879A MX2009012879A MX 2009012879 A MX2009012879 A MX 2009012879A MX 2009012879 A MX2009012879 A MX 2009012879A MX 2009012879 A MX2009012879 A MX 2009012879A MX 2009012879 A MX2009012879 A MX 2009012879A
Authority
MX
Mexico
Prior art keywords
tyrosine kinase
receptor tyrosine
rtki
eye
delivery
Prior art date
Application number
MX2009012879A
Other languages
Spanish (es)
Inventor
Rajni Jani
Wesley Wehsin Han
Huixiang Zhang
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of MX2009012879A publication Critical patent/MX2009012879A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to development of efficacious pharmaceutical ophthalmic compositions comprising a poorly water soluble active compound in a therapeutically effective amount and a polyethylene co-solvent in a suitable amount to treat or prevent diseases due to ocular neovascularization and enhanced vascular permeability. The composition is in the form of a gel, and the prefered active compound is the multi-targeted receptor tyrosine kinase' inhibitor N- [4- (3-amino-lH-indazol-4-yl) phenye] -N- (2-f luoro-5-methylphenye) urla].
MX2009012879A 2007-07-20 2007-07-20 Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye. MX2009012879A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2006/062359 WO2009014510A1 (en) 2007-07-20 2007-07-20 Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye

Publications (1)

Publication Number Publication Date
MX2009012879A true MX2009012879A (en) 2010-01-14

Family

ID=39226747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012879A MX2009012879A (en) 2007-07-20 2007-07-20 Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye.

Country Status (9)

Country Link
EP (1) EP2178564A1 (en)
JP (1) JP2010534201A (en)
KR (1) KR20100051811A (en)
CN (1) CN101687042A (en)
AU (1) AU2007356856A1 (en)
BR (1) BRPI0721885A2 (en)
CA (1) CA2693888A1 (en)
MX (1) MX2009012879A (en)
WO (1) WO2009014510A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
US8912236B2 (en) 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
JP5583145B2 (en) * 2009-03-03 2014-09-03 アルコン リサーチ， リミテッド Pharmaceutical compositions for ocular delivery of receptor tyrosine kinase inhibitor (RTKi) compounds
KR20110130454A (en) * 2009-03-03 2011-12-05 알콘 리서치, 리미티드 Pharmaceutical composition for delivering receptor tyrosine kinase inhibitory (RＴＫｉ) compounds to the eye
KR20130094293A (en) * 2010-07-21 2013-08-23 알콘 리서치, 리미티드 Pharmaceutical composition with enhanced solubility characteristics
EA201690621A1 (en) 2013-09-20 2016-07-29 Сантен Фармасьютикал Ко., Лтд. POLYETHYLENE GLYCOL-CONTAINING COMPOSITIONS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2703777A (en) * 1950-05-02 1955-03-08 Iso Sol Company Inc Ophthalmological preparations and vehicles and method of making the same
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US5443824A (en) * 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
RU2125427C1 (en) * 1998-05-27 1999-01-27 Миронова Эмилия Михайловна Okovidit c eye disease drug
EP1437143A4 (en) * 2001-09-28 2007-05-09 Santen Pharmaceutical Co Ltd Injections for eye tissue containing drug bound to polyethylene glycol
WO2004073608A2 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Formulations of glucocorticoids to treat pathologic ocular angiogenesis
BRPI0607606B1 (en) * 2005-02-09 2021-06-22 Santen Pharmaceutical, Co., Ltd. LIQUID FORMULATION
TW200640443A (en) * 2005-02-23 2006-12-01 Alcon Inc Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors
WO2006094064A2 (en) * 2005-02-28 2006-09-08 Avocet Polymer Technologies, Inc. Method of reducing scars with vitamin d
JP2009521493A (en) * 2005-12-23 2009-06-04 アルコン，インコーポレイテッド Pharmaceutical formulations for delivery of receptor tyrosine kinase inhibition (RTKi) compounds to the eye

Also Published As

Publication number Publication date
BRPI0721885A2 (en) 2014-02-25
JP2010534201A (en) 2010-11-04
EP2178564A1 (en) 2010-04-28
CA2693888A1 (en) 2009-01-29
KR20100051811A (en) 2010-05-18
CN101687042A (en) 2010-03-31
AU2007356856A1 (en) 2009-01-29
WO2009014510A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
TW200733958A (en) Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
MX2011008731A (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye.
KR101343291B1 (en) Pharmaceutical composition for external use
MX2009012879A (en) Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye.
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
EP3634415B1 (en) Ophthalmological compositions comprising brimonidine and ketotifen for use in the treatment of allergies
EP2178870A4 (en) INDOLE AND INDAZOLE COMPOUNDS AS INHIBITORS OF CELL NECROSIS
WO2007076360A8 (en) (indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)- pyrazines for treating rho kinase-mediated diseases and conditions
UA84318C2 (en) Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists, pharmaceutical composition based thereon
RS53417B (en) POLYMER LIBRARY SYSTEM FOR SINGLE-VISCOSE SOLUTION BASED ON PROSTAGLANDIN WITHOUT CONSERVATORS
RU2015107877A (en) METHODS FOR TREATING ALZHEIMER'S DISEASE AND PHARMACEUTICAL COMPOSITIONS
MX2011008680A (en) Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye.
TWI832920B (en) Ophthalmic composition for preventing deterioration of soft contact lenses
TNSN05164A1 (en) 2- (1H-INDAZOL-6-YLAMINO) -BENZAMIDES AS INHIBITORS OF PROTEIN KINASES USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES
JP2017503028A (en) Compositions and methods for treating intraocular neovascularization and / or leakage
MA32639B1 (en) [4 - (5-aminomethyl-2-fluoro-phenyl) -piperidine-1-yl]-[7 fluoro-1-(2-methoxyethyl) -4-thalate fluoro-methoxy-1h-indole-3yl] methane as Anti-tryptase mast cells
AR069349A1 (en) USE OF TRPV1 RECEIVER ANTAGONISTS FOR THE TREATMENT OF THE EYE AND EYE PAIN
CA3045004A1 (en) Methods and compositions for treating peripheral neuropathy
TW200733959A (en) Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
MA30313B1 (en) SECONDARY AMINES AS RENIN INHIBITORS
MX2024014626A (en) Methods of treating chronic spontaneous urticaria using a bruton's tyrosine kinase inhibitor
Seong et al. Autophagy precedes apoptosis in angiotensin II-induced podocyte injury
TW201206418A (en) Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease
US20200108064A1 (en) Low-dose brimonidine combinations and uses thereof
TW200946113A (en) PAI-1 expression and activity inhibitors for the treatment of ocular disorders

Legal Events

Date Code Title Description
FA Abandonment or withdrawal